Junshi CEO Ning Li (Junshi)
September 29, 2020 07:13 AM EDT
R&D

Rac­ing ahead of Mer­ck and In­novent, Jun­shi de­clares PhI­II suc­cess on can­cer that won them 'break­through' sta­tus

Jason Mast

Editor

Ear­ly this month, the FDA hand­ed Jun­shi Bio­sciences an agency first: A break­through des­ig­na­tion for a PD-(L)1 ther­a­py out of Chi­na. Now, the Shang­hai …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times